Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

被引：0
|
作者：
A F List
J M Bennett
M A Sekeres
B Skikne
T Fu
J M Shammo
S D Nimer
R D Knight
A Giagounidis
机构：
来源：
Leukemia | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2014) 28, 1033–1040; doi:10.1038/leu.2013.305 Since the publication of this article it has been noted that there was an omission in the listing of conflict of interest. JM Bennett was listed as having no conflict of interest; however, the authors would like to correct this to read:
引用
收藏
页码：2452 / 2452
相关论文
共 50 条
  • [1] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2014, 28 : 1033 - 1040
  • [2] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2014, 28 (05) : 1033 - 1040
  • [3] Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS (vol 28, pg 1033, 2014)
    List, A. F.
    Bennett, J. M.
    Sekeres, M. A.
    Skikne, B.
    Fu, T.
    Shammo, J. M.
    Nimer, S. D.
    Knight, R. D.
    Giagounidis, A.
    LEUKEMIA, 2015, 29 (12) : 2452 - 2452
  • [4] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
  • [5] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    Sekeres, M. A.
    Swern, A. S.
    Fenaux, P.
    Greenberg, P. L.
    Sanz, G. F.
    Bennett, J. M.
    Dreyfus, F.
    List, A. F.
    Li, J. S.
    Sugrue, M. M.
    BLOOD CANCER JOURNAL, 2014, 4 : e242 - e242
  • [6] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Pierre Fenaux
    Aristoteles Giagounidis
    Dominik Selleslag
    Odile Beyne-Rauzy
    Moshe Mittelman
    Petra Muus
    Stephen D. Nimer
    Eva Hellström-Lindberg
    Bayard L. Powell
    Agnes Guerci-Bresler
    Mikkael A. Sekeres
    H. Joachim Deeg
    Consuelo del Cañizo
    Peter L. Greenberg
    Jamile M. Shammo
    Barry Skikne
    Xujie Yu
    Alan F. List
    Journal of Hematology & Oncology, 10
  • [7] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Beyne-Rauzy, Odile
    Mittelman, Moshe
    Muus, Petra
    Nimer, Stephen D.
    Hellstrom-Lindberg, Eva
    Powell, Bayard L.
    Guerci-Bresler, Agnes
    Sekeres, Mikkael A.
    Deeg, H. Joachim
    del Canizo, Consuelo
    Greenberg, Peter L.
    Shammo, Jamile M.
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [8] Risk factors for disease progression in del(5q) MDS patients treated with lenalidomide
    Giagounidis, Aristoteles A.
    Haase, Sabine
    Platzbecker, Uwe
    Germing, Ulrich
    Lohrbacher, Vera
    Ehninger, Gerhard
    Aul, Carlo
    BLOOD, 2007, 110 (11) : 437A - 437A
  • [9] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [10] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
12345